Aethlon Medical (AEMD) Schedule 13G: 576,603 Shares (7.7%)
Aethlon Medical, Inc. reporting persons Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC filed a Schedule 13G disclosing potential and actual beneficial ownership related to a September 4, 2025 Securities Purchase Agreement.
Rhea-AI Filing Summary
Aethlon Medical, Inc. reporting persons Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC filed a Schedule 13G disclosing potential and actual beneficial ownership related to a September 4, 2025 Securities Purchase Agreement. The filing explains that, before blocker provisions are applied, each reporting person could have been deemed to beneficially own 1,111,110 shares. As of the close of business on September 10, 2025, each reporting person is reported as beneficially owning 576,603 shares, representing approximately 7.7% of the common stock. The ownership includes 21,048 shares held by Intracoastal and 555,555 shares issuable upon exercise of a warrant, and the filing describes blocker provisions limiting exercise to prevent ownership above 9.99%.
Positive
- Transparent disclosure of beneficial ownership, including exact share counts and warrant details
- Inclusion of blocker provisions that clearly limit warrant exercise above 9.99%, reducing ambiguity about potential control shifts
- Joint Filing Agreement and certifications included and properly executed, supporting regulatory compliance
Negative
- Significant warrant exposure (555,555 shares issuable) creates potential dilution overhang, even though exercise is limited by blockers
- Shared voting power but no sole control indicates coordinated influence rather than clear single-party governance authority
Insights
TL;DR: Reporting group holds 7.7% post-transaction with material warrant exposure, constrained by 9.99% blocker provisions.
The Schedule 13G discloses a meaningful minority position in Aethlon Medical resulting from a Securities Purchase Agreement executed September 4, 2025. The group reports aggregate beneficial ownership of 576,603 shares (7.7%) as of September 10, 2025, including a large tranche of warrants (555,555 shares issuable) and a smaller direct holding (21,048 shares). The filing clearly documents blocker provisions that cap exercise rights to avoid exceeding 9.99%, which materially affects potential dilution and near-term conversion dynamics. The disclosure is precise and compliant, enabling investors to quantify the groups stake and warrant-related overhang.
TL;DR: The filing shows shared voting/dispositive power without sole control and includes required certifications and a joint filing agreement.
The report indicates shared voting power of 576,603 shares and shared dispositive power of 555,555 shares, with no sole voting or dispositive power recorded. Signatures from both individuals and Intracoastals manager accompany the filing and the exhibit list includes a Joint Filing Agreement, demonstrating coordinated disclosure. The certification affirms the securities were not acquired to change control. These elements speak to proper governance disclosure and clarify that the position is a collective, not unilateral, control attempt.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What transaction prompted this Schedule 13G filing for AEMD?
Are there warrants included in the reported ownership for AEMD?
What limits exist on exercising warrants disclosed in the filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.